Mode
Text Size
Log in / Sign up
Phase 1 Completed N=39 Randomized Basic Science

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Source: ClinicalTrials.gov NCT04616027 ↗
Enrolled (actual)
39
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961 — 38.80; 38.67; 39.19; 56.68 nanograms/milliliter (ng/mL)

Summary

This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.

Outcome Measures

OutcomeResultp-value
PRIMARY
Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961
38.80; 38.67; 39.19; 56.68; 39.18
PRIMARY
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961
362.4; 404.8; 487.0; 543.2; 408.8
PRIMARY
Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961
359.9; 399.6; 466.3; 538.2; 404.8
PRIMARY
Fraction Unbound (fu) of Plasma PF-06882961
0.01519; 0.01542; 0.01699; 0.01861; 0.01960
SECONDARY
Maximum Observed Concentration of Unbound Drug (Cmax,u) of Plasma PF-06882961
0.5896; 0.5963; 0.6662; 1.055; 0.7680
SECONDARY
Unbound Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf,u) of Plasma PF-06882961
5.505; 6.246; 7.931; 10.01; 8.019
SECONDARY
Unbound Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,u) of Plasma PF-06882961
5.470; 6.162; 7.922; 10.01; 7.927
SECONDARY
Apparent Clearance (CL/F) of Plasma PF-06882961
55.17; 49.32; 41.08; 36.83; 48.93
SECONDARY
Apparent Clearance of Unbound Drug After Oral Administration (CLu/F) of Plasma PF-06882961
3631; 3200; 2525; 2000; 2494
SECONDARY
Apparent Volume of Distribution (Vz/F) of Plasma PF-06882961
600.8; 552.3; 372.5; 438.4; 565.9
SECONDARY
Unbound Vz/F (Vz,u/F) of Plasma PF-06882961
39530; 35810; 22890; 23800; 28900
SECONDARY
Time of Observed Maximum Plasma Concentration (Tmax) of Plasma PF-06882961
5.00; 5.00; 6.00; 5.50; 5.00
SECONDARY
Terminal Elimination Half-Life (T1/2) of Plasma PF-06882961
8.111; 8.139; 6.640; 8.907; 8.058
SECONDARY
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities)
1; 6; 1; 2; 2; 0
SECONDARY
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
0; 0; 0; 0; 1; 0
SECONDARY
Number of Participants With Abnormal Vital Signs
0; 0; 0; 0; 0; 0
SECONDARY
Number of Participants With Abnormal Electrocardiograms (ECGs)
0; 0; 0; 0; 0; 0

Eligibility Criteria

Inclusion Criteria

  • Stable renal function (for participants not on dialysis) defined as ≤25% difference between 2 measurements of eGFR (as calculated by the sponsor-identified central laboratory using the CKD-EPI equation)1 obtained at Screening visits S1 and S2. The average of the 2 eGFR values obtained from S1 and S2 will be used for study enrollment and assignment to appropriate renal function group. Note: participants on dialysis will be placed in Group 5 regardless of eGFR from S1 and S2 (S2 is optional for dialysis participants only).
  • Male and female participants must be ≥18 years of age, inclusive, at the time of signing the informed consent document (ICD).
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures, including the ability to perform self-monitoring blood glucose at a frequency deemed appropriate by the investigator.
  • Body mass index (BMI) of ≥18.0 kg/m2 and 50 kg (110 lb).
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Additional Inclusion Criteria for Healthy Participants with Normal Renal

Function (Group 1):

  • No clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure (BP) and pulse rate measurement, standard 12-lead ECG and clinical laboratory tests.
  • Normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from Screening visits S1 and S2.
  • Demographically comparable to participants with impaired renal function:
  • A body weight within ±15 kg of the mean body weight of the pooled renal impairment groups (Groups 3, 4, and 5), as provided by sponsor;
  • An age within ±10 years of the mean age of the pooled renal impairment groups (Groups 3, 4 and 5), as provided by sponsor;
  • Attempts will be made to ensure that the male to female distribution in Group 1 is comparable to that in the pooled renal impairment groups (Cohorts 3, 4, and 5).

Additional Inclusion Criteria for T2DM Participants with Normal Renal

Function (Group 2):

  • A prior diagnosis of T2DM with an HbA1c ≥6% and ≤10.5%, at Screening visit S1, confirmed by a single repeat, if deemed necessary.
  • Normal renal function (mean eGFR ≥90 mL/min) based on an average of measures from Screening visits S1 and S2.
  • Prohibited prior/concomitant medications.
  • Demographically comparable to participants with impaired renal function:
  • A body weight within ±15 kg of the mean body weight of the pooled renal impairment groups (Groups 3, 4, and 5), as provided by sponsor;
  • An age within ±10 years of the mean age of the pooled renal impairment groups (Groups 3, 4, and 5), as provided by sponsor;
  • Attempts will be made to ensure that the male to female distribution in Group 2 is comparable to that in the pooled renal impairment groups (Cohorts 3, 4, and 5).

Additional Inclusion Criteria for T2DM Participants with Impaired Renal Function (Groups 3-5):

  • A prior diagnosis of T2DM with an HbA1c ≥6% and ≤10.5%, at Screening visit S1, confirmed by a single repeat, if deemed necessary.
  • Meet the eGFR criteria listed for Groups 3, 4, or 5 (for participants not on dialysis) in Table 1 based on an average of measures from Screening visits S1 and S2.
  • Stable concomitant medications, as defined in Section 6.5, for the management of medical conditions relevant to an individual participant's medical history. Participants receiving fluctuating concomitant medications/treatments may be considered, on a case-by-case basis with input from sponsor, if the underlying disease is stable.
  • For Group 5 participants on dialysis only, participants must have required hemodialysis for at least 6 weeks and need dialysis sessions 3 times per week

Exclusion Criteria

  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or act
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04616027). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search